Seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in children: a field guide

Overview

Since 2012, WHO has recommended SMC for children aged 3 to 59 months during the high-transmission season in Africa’s Sahel sub-region. The provision of this preventive therapy at monthly intervals has been shown to have a significant protective effect against uncomplicated and severe malaria.

This field guide provides the necessary technical and operational information and tools to guide decisions by country-level policy-makers and programme managers around the adoption and implementation of SMC.